CLINICAL_TRIALS
trial_result
· 2015-05-12
Clinical Trial Update: A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing [Phase 3]
Summary
Phase 3 study evaluating short-term dosing of fluoxetine in Major Depressive Disorder has completed. Results were posted in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2015-05-12